This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

26 Jan 2011

Sanofi Acquires License for Antibody from Oxford

Sanofi-Aventis has acquired an exclusive worldwide license to one of OBT’s antibody programs.

Sanofi-aventis has acquired a license to one of Oxford BioTherapeutics’ (OBT) preclinical antibody programs. Sanofi-Aventis intends to use the licensed antibody, which is directed against a novel, proprietary target identified by OBT, to develop, manufacture and commercialize antibody drug conjugate (ADC) products for the treatment of cancer. ADC products comprise toxins attached to antibodies, which creates highly targeted therapeutic products that attack tumor cells.

OBT will receive an undisclosed upfront cash payment and is eligible to receive development and regulatory milestone payments, royalties on the worldwide products sales, and performance-based milestones.

“This is the most advan

Related News